Early metastatic cancer of unknown primary origin at presentation. A clinical study of 302 consecutive autopsied patients.

We studied 302 consecutive autopsied patients who presented with carcinoma of unknown primary origin. The most frequent metastatic sites were the nodes, lung, and bone. The primary site was identified while patients were alive in 27% and at autopsy in 57%; the site remained unidentified in 16%. The pancreas (26.5%), lung (17.2%), kidney (4.6%), and colorectum (3.6%) were the most frequent primary sites, but the reliability of diagnostic tests used in the search for this site was disappointing. Survival was identical in patients whose primary site was discovered while alive, at autopsy, or remained unknown. The number of metastases at presentation was the major prognostic factor. Analysis of autopsy data demonstrated that patients with carcinoma of unknown primary origin pursue a different course than expected when the primary site is the first manifestation of the disease. On the basis of these results and the results of other modern series, we suggest an approach consisting of a limited initial workup but with greater emphasis on modern histochemistry studies and immunohistopathologic and other kinetic and morphologic parameters to understand the patient tumor characteristics better and base the clinical management on an individual basis.

[1]  M. Viola,et al.  Identifying the primary site in metastatic cancer of unknown origin. Inadequacy of roentgenographic procedures. , 1979, JAMA.

[2]  J. Meyer Potential value of cell kinetics in management of cancers of unknown origin. , 1982, Seminars in oncology.

[3]  C. Moertel Adenocarcinoma of unknown origin. , 1979, Annals of internal medicine.

[4]  E. Silverberg Cancer statistics, 1984 , 1984, CA: a cancer journal for clinicians.

[5]  Nystrom Js,et al.  Metastatic cancer of unknown origin: nonsquamous cell type. , 1982 .

[6]  F. Greco,et al.  The extragonadal germ cell cancer syndrome. , 1982, Seminars in oncology.

[7]  M. Nissenblatt The CUP syndrome (carcinoma unknown primary). , 1981, Cancer treatment reviews.

[8]  R. Wilson,et al.  In pursuit of the unknown primary. , 1978, American journal of surgery.

[9]  N. Ordóñez,et al.  The role of the pathologist in the evaluation of poorly differentiated tumors. , 1982, Seminars in Oncology.

[10]  M. Pike,et al.  Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. analysis and examples. , 1977, British Journal of Cancer.

[11]  H. Sakahara,et al.  Serum CA 19‐9 concentrations and computed tomography findings in patients with pancreatic carcinoma , 1986, Cancer.

[12]  Norman Goldstein,et al.  Metastases in carcinoma. Analysis of 1000 autopsied cases , 1950, Cancer.

[13]  D. Alberts,et al.  Quantitation of differential sensitivity of human-tumor stem cells to anticancer drugs. , 1978, The New England journal of medicine.

[14]  F. Holmes,et al.  Metastatic cancer of unknown primary site , 1970, Cancer.

[15]  D. Mclain,et al.  Metastatic carcinoma of the pancreas simulating primary bronchogenic carcinoma , 1980, Cancer.

[16]  D. Kiang,et al.  Estrogen receptor assay in the differential diagnosis of adenocarcinomas. , 1977, JAMA.

[17]  E. Copeland,et al.  Axillary Metastases from Unknown Primary Sites , 1973, Annals of surgery.

[18]  M. B. Rosenblatt,et al.  Pitfalls in the clinical histologic diagnosis of bronchogenic carcinoma. , 1966, Diseases of the chest.

[19]  C. Clary,et al.  Metastatic carcinoma: The lung as the site for the clinically undiagnosed primary , 1983, Cancer.

[20]  L. Weisenthal,et al.  A novel dye exclusion method for testing in vitro chemosensitivity of human tumors. , 1983, Cancer research.

[21]  P. Sheedy,et al.  Computed tomography in search of cancer of unknown origin. , 1982, JAMA.

[22]  E. Casper,et al.  Adenocarcinoma of unknown primary origin: treatment with vindesine and doxorubicin. , 1985, Cancer treatment reports.

[23]  M. Valdivieso,et al.  Adenocarcinoma of unknown primary site: a clinico-pathological study. , 1979, Medical and pediatric oncology.

[24]  M. Koch,et al.  Carcinoembryonic antigen levels as an indicator of the primary site in metastatic disease of unknown origin , 1981, Cancer.

[25]  M. Dy,et al.  The use of monoclonal antibodies for histopathologic diagnosis of human malignancy. , 1982, Seminars in oncology.

[26]  B. Caillou,et al.  Long‐term results and prognostic factors in patients with differentiated thyroid carcinoma , 1985, Cancer.

[27]  E. Cadman,et al.  An analysis of 1539 patients with cancer of unknown primary site , 1986, Cancer.

[28]  E. Levine,et al.  Computed tomography in the evaluation of metastatic adenocarcinoma from an unknown primary site. A retrospective study. , 1982, Radiology.

[29]  M. Tattersall,et al.  Metastatic adenocarcinomas of unknown primary site: a randomized study of two combination-chemotherapy regimens. , 1980, The New England journal of medicine.

[30]  E. Elias,et al.  Metastatic Carcinomas from Occult Primary Tumors: A Study of 254 Patients , 1977, Annals of surgery.

[31]  J. M. Young,et al.  Pulmonary metastasis from occult primary sites resembling bronchogenic carcinoma. , 1958, Diseases of the chest.

[32]  G. Bodey,et al.  Adenocarcinoma of unknown primary origin: impact of chemotherapy on survival. , 1981, Southern medical journal.